Statin treatment alters serum n-3 to n-6 polyunsaturated fatty acids ratio in patients with dyslipidemia

Table 3 Effects of rosuvastatin and pitavastatin on serum PUFAs levels and their ratios

		Baseline	4 weeks	p value	12 weeks	p value
EPA (μg/mL)	Rosuvastatin	66.9 (28.9-199.9)	70.2 (31.5-156.7)	0.69	64. 8 (23.7-216.9)	0.83
EPA (μg/mL)	Pitavastatin	87.0 (15.2-149.8)	65.6 (16.0-201.5)	0.06	79.8 (17.8-205.0)	0.51
DHA (μg/mL)	Rosuvastatin	169.6 (98.1-384-6)	142.5 (66.0-215.6)	0.005	136.3 (56.0-251.9)	0.006
DHA (μg/mL)	Pitavastatin	188.6 (91.8-283.6)	135.2 (80.3-198.8)	0.0004	153.9 (93.8-250.4)	0.03
DGLA (μg/mL)	Rosuvastatin	36.2 (18.1-74.4)	34.2 (18.3-53.3)	0.06	33.6 (17.1-56.5)	0.18
DGLA (μg/mL)	Pitavastatin	37.4 (18.4-57.3)	35.4 (20.0-53.5)	0.13	36.7 (23.5-58.9)	0.48
AA (μg/mL)	Rosuvastatin	168.3 (114.6-284.9)	158.3 (104.2-276.7)	0.43	163.2 (88.9-269.2)	0.81
AA (μg/mL)	Pitavastatin	167.3 (106.0-279.2)	166.0 (102.0-242.6)	0.89	180.2 (97.0-236.9)	0.2
EPA/AA	Rosuvastatin	0.42 (0.13-1.65)	0.44 (0.13-1.45)	0.36	0.37 (0.10-1.48)	0.91
EPA/AA	Pitavastatin	0.51 (0.07-1.19)	0.38 (0.07-1.27)	0.14	0.43 (0.08-1.18)	0.25
DHA/AA	Rosuvastatin	0.99 (0.42-1.82)	0.81 (0.37-1.69)	0.05	0.80 (0.35-1.76)	0.01
DHA/AA	Pitavastatin	1.14 (0.08-1.18)	0.87 (0.37-1.77)	0.0002	0.91 (0.45-1.59)	0.003
EPA + DHA/AA	Rosuvastatin	1.42 (0.55-3.34)	1.25 (0.50-3.14)	0.54	1.25 (0.45-2.88)	0.07
EPA + DHA/AA	Pitavastatin	1.75 (0.52-2.85)	1.22 (0.44-2.89)	0.002	1.34 (0.53-2.64)	0.03

Data are expressed as median (range)
PUFAs, polyunsaturated fatty acids; EPA, eicosapentaenoic acid; DHA, docosahexaenoic acid; DGLA, dihomogamma-linolenic acid; AA, arachidonic acid

ISSN: 1476-511X